For investors seeking opportunities within the biotechnology sector, Apellis Pharmaceuticals, Inc. (APLS) presents a compelling case. With a market capitalization of $2.84 billion, this Massachusetts-based company is carving out its niche in the healthcare landscape by focusing on innovative therapies for diseases with significant unmet needs.

Apellis’s flagship products, EMPAVELI and SYFOVRE, target conditions such as paroxysmal nocturnal hemoglobinuria and geographic atrophy secondary to age-related macular degeneration, respectively. Additionally, the company is expanding its pipeline with potential treatments for complex renal diseases and other complement-driven conditions, enhanced by strategic partnerships with industry…